← Sol-Gel Technologies Ltd. (SLGL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Sol-Gel Technologies Ltd. (SLGL)
Pharmaceutical Preparations · market cap $172M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-19 (est.)
Earnings
Pipeline
8
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Sol-Gel Technologies (SLGL) is a specialty pharmaceutical company with 34 employees and a ~$241M market cap, trading at ~$76.36. The company has a deep Phase 3 pipeline spanning dermatology indications including Gorlin Syndrome (Basal Cell Nevus Syndrome), acne vulgaris, papulopustular rosacea, and actinic keratosis. The near-term focus is a high-importance Phase 3 readout for Patidegib Topical Gel in Gorlin Syndrome, estimated around August 15, 2026.
The catalyst path
- 2026-11-19 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Patidegib Topical Gel | Phase 3 | Gorlin Syndrome |
| S6G5T-3 | Phase 3 | Acne Vulgaris |
| Patidegib Topical Gel, 2% | Phase 3 | Basal Cell Nevus Syndrome |
| S5G4T-2 | Phase 3 | Papulopustular Rosacea |
| S5G4T-1 | Phase 3 | Papulopustular Rosacea |
| 5-FU Cream | Phase 3 | Actinic Keratosis (AK) |
| DER 45 EV | Phase 2 | Rosacea |
| S6G5T-8 | Phase 3 | Acne Vulgaris |
Price & technical context
3-month
-1.4%
6-month
-12.6%
12-month
+150.4%
52-wk range
$29.50–$97.97
vs 50-day MA
-1.8%
vs 200-day MA
+1.7%
Realized vol
86.1%
Max drawdown
-75.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SLGL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.